Trials (Feb 2022)

Intranasal dexamethasone: a new clinical trial for the control of inflammation and neuroinflammation in COVID-19 patients

  • Graciela Cárdenas,
  • María Chávez-Canales,
  • Ana María Espinosa,
  • Antonio Jordán-Ríos,
  • Daniel Anica Malagon,
  • Manlio Fabio Márquez Murillo,
  • Laura Victoria Torres Araujo,
  • Ricardo Leopoldo Barajas Campos,
  • Rosa María Wong-Chew,
  • Luis Esteban Ramirez González,
  • Karent Ibet Cresencio,
  • Enrique García Velázquez,
  • Mariana Rodriguez de la Cerda,
  • Yoana Leyva,
  • Joselin Hernández-Ruiz,
  • María Luisa Hernández-Medel,
  • Mireya León-Hernández,
  • Karen Medina Quero,
  • Anahí Sánchez Monciváis,
  • Sergio Hernández Díaz,
  • Ignacia Rosalia Zeron Martínez,
  • Adriana Martínez-Cuazitl,
  • Iván Noé Martínez Salazar,
  • Eduardo Beltrán Sarmiento,
  • Aldo Figueroa Peña,
  • Patricia Saraí Hernández,
  • Rafel Ignacio Aguilar Reynoso,
  • Daniela Murillo Reyes,
  • Luis Rodrigo del Río Ambriz,
  • Rogelio Antonio Alfaro Bonilla,
  • Jocelyn Cruz,
  • Leonor Huerta,
  • Nora Alma Fierro,
  • Marisela Hernández,
  • Mayra Pérez-Tapia,
  • Gabriela Meneses,
  • Erick Espíndola-Arriaga,
  • Gabriela Rosas,
  • Alberto Chinney,
  • Sergio Rosales Mendoza,
  • Juan Alberto Hernández-Aceves,
  • Jaquelynne Cervantes-Torres,
  • Anai Fuentes Rodríguez,
  • Roxana Olguin Alor,
  • Sandra Ortega Francisco,
  • Evelyn Alvarez Salazar,
  • Hugo Besedovsky,
  • Marta C. Romano,
  • Raúl J. Bobes,
  • Helgi Jung,
  • Gloria Soldevila,
  • Juan López-Alvarenga,
  • Gladis Fragoso,
  • Juan Pedro Laclette,
  • Edda Sciutto

DOI
https://doi.org/10.1186/s13063-022-06075-5
Journal volume & issue
Vol. 23, no. 1
pp. 1 – 11

Abstract

Read online

Highlights REVIVAL is a multicenter, open-label, randomized, controlled study to compare the standard low doses of intravenous dexamethasone with weight-adjusted low doses of intranasal dexamethasone. Intranasal dexamethasone can reach the respiratory tract more effectively than intravenous administration. Intranasal dexamethasone can reach the central nervous system in therapeutic concentrations, even at low doses. REVIVAL aims to reduce central failures and sequelae by controlling not only systemic inflammation but also neuroinflammation.

Keywords